γ-glutamyl-threonine | 5652-48-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: γ-glutamyl-threonine
• 英文别名: γ-Glu-Thr；gamma-Glutamylthreonine；(2S)-2-amino-5-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-5-oxopentanoic acid
• CAS: 5652-48-2
• 化学式: C₉H₁₆N₂O₆
• 分子量: 248.236
• InChiKey: GWNXFCYUJXASDX-ZDLURKLDSA-N

物化性质

• 沸点：
  621.8±55.0 °C(Predicted)
• 密度：
  1.421±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -4.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  150
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  L-苏氨酸 、 monosodium L-glutamate 在 adenosine 5'-triphosphate sodium salt 、 magnesium chloride 、 bovine serum albumin 作用下， 反应 24.0h， 以37.1%的产率得到γ-glutamyl-threonine
  参考文献：
  名称：

  Nakayama, Reiko; Kumagai, Hedehiko; Maruyama, Takashi, Agricultural and Biological Chemistry, 1981, vol. 45, # l2, p. 2839 - 2846

  摘要：

  DOI：

文献信息

• Biomarkers for cardiovascular diseases and methods using the same
  申请人：Metabolon, Inc.

  公开号：US10175233B2

  公开（公告）日：2019-01-08

  Biomarkers relating to cardiovascular disease, including atherosclerosis and cardiomyopathy, are provided, as well as methods for using such biomarkers as biomarkers for cardiovascular disease. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for cardiovascular disease, including atherosclerosis and cardiomyopathy.

  本研究提供了与心血管疾病（包括动脉粥样硬化和心肌病）有关的生物标志物，以及将此类生物标志物用作心血管疾病生物标志物的方法。此外，还提供了调节受试者相应疾病或状况的方法。还提供了作为心血管疾病（包括动脉粥样硬化和心肌病）生物标志物的成套小分子实体。
• Biomarkers related to organ function
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10634686B2

  公开（公告）日：2020-04-28

  Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.

  本文公开了鉴定可用于预测器官或组织功能或功能障碍的生物标记物（如基因（如 RNA 或 mRNA）、蛋白质和/或小分子）的方法。在一些实施方案中，这些方法包括对器官或组织进行体外灌注，收集器官或组织的样本（例如灌注液、器官产生的液体（如胆汁或尿液）或组织活检），并测量样本中一种或多种生物标记物的水平。本文还公开了对来自器官、组织或受试者的生物样本中存在的生物标记物（如基因（如 RNA 或 mRNA）、蛋白质和/或小分子）的分析，可用于确定器官、组织或受试者是否有器官功能障碍或器官衰竭的风险（或已出现器官功能障碍或器官衰竭）。
• Automated sample quality assessment
  申请人：Metabolon, Inc.

  公开号：US10890592B2

  公开（公告）日：2021-01-12

  A method of assessing the quality of a biological sample while maintaining the viability of the biological sample for intended use analysis is described herein. The method includes analyzing a biological sample obtained from a subject for an intended use, assessing the quality of the biological sample using one or more biomarkers of sample quality, and simultaneously performing intended use analysis on the same sample. Assessing the quality of the sample can include assessing compliance with sample handling protocols and assessing subject compliance.

  本文描述了一种评估生物样本质量的方法，同时保持生物样本的活力，以便进行预期用途分析。该方法包括分析从受试者处获得的用于预期用途的生物样本，使用一个或多个样本质量生物标志物评估生物样本的质量，并同时对同一样本进行预期用途分析。评估样本质量可包括评估样本处理协议的合规性和评估受试者的合规性。
• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。
• BIOMARKERS FOR PRE-DIABETES AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP2164977B1

  公开（公告）日：2013-10-30